POLY MEDICURE LIMITED Financials Poly Medicure Limited
Equities
POLYMED
INE205C01021
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,639 INR | -0.02% |
|
+7.14% | +9.97% |
| Feb. 02 | Transcript : Poly Medicure Limited, Q3 2024 Earnings Call, Feb 02, 2024 | |
| Jan. 31 | Poly Medicure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: März | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 20,791 | 78,392 | 90,990 | 91,445 | 157,363 | - | - |
| Enterprise Value (EV) 1 | 20,791 | 78,392 | 90,990 | 91,445 | 155,855 | 154,718 | 152,929 |
| P/E ratio | - | 53.6 x | 62.1 x | 51 x | 61.6 x | 47.8 x | 37.6 x |
| Yield | - | 0.31% | 0.26% | 0.31% | 0.3% | 0.36% | 0.46% |
| Capitalization / Revenue | 3.03 x | 9.97 x | 9.86 x | 8.2 x | 11.5 x | 9.45 x | 7.78 x |
| EV / Revenue | 3.03 x | 9.97 x | 9.86 x | 8.2 x | 11.4 x | 9.29 x | 7.56 x |
| EV / EBITDA | - | 36.6 x | 42.7 x | 34.5 x | 43.6 x | 33.7 x | 26.6 x |
| EV / FCF | - | 332 x | -297 x | -189 x | 171 x | 76.4 x | 56.6 x |
| FCF Yield | - | 0.3% | -0.34% | -0.53% | 0.58% | 1.31% | 1.77% |
| Price to Book | - | 7.55 x | 8.37 x | 7.36 x | 10.9 x | 9.21 x | 7.69 x |
| Nbr of stocks (in thousands) | 88,247 | 95,881 | 95,900 | 95,944 | 95,971 | - | - |
| Reference price 2 | 235.6 | 817.6 | 948.8 | 953.1 | 1,640 | 1,640 | 1,640 |
| Announcement Date | 6/5/20 | 5/24/21 | 5/24/22 | 5/9/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 6,872 | 7,865 | 9,231 | 11,152 | 13,636 | 16,659 | 20,231 |
| EBITDA 1 | - | 2,144 | 2,131 | 2,654 | 3,572 | 4,598 | 5,740 |
| EBIT 1 | - | 1,668 | 1,616 | 2,082 | 2,906 | 3,878 | 4,984 |
| Operating Margin | - | 21.21% | 17.51% | 18.67% | 21.31% | 23.28% | 24.63% |
| Earnings before Tax (EBT) 1 | - | 1,801 | 1,952 | 2,375 | 3,376 | 4,365 | 5,561 |
| Net income 1 | - | 1,359 | 1,465 | 1,793 | 2,546 | 3,288 | 4,187 |
| Net margin | - | 17.28% | 15.87% | 16.08% | 18.67% | 19.74% | 20.69% |
| EPS 2 | - | 15.24 | 15.27 | 18.67 | 26.60 | 34.28 | 43.66 |
| Free Cash Flow 1 | - | 236 | -305.9 | -483 | 911.5 | 2,026 | 2,700 |
| FCF margin | - | 3% | -3.31% | -4.33% | 6.68% | 12.16% | 13.34% |
| FCF Conversion (EBITDA) | - | 11.01% | - | - | 25.52% | 44.07% | 47.03% |
| FCF Conversion (Net income) | - | 17.37% | - | - | 35.8% | 61.63% | 64.49% |
| Dividend per Share 2 | - | 2.500 | 2.500 | 3.000 | 4.925 | 5.825 | 7.475 |
| Announcement Date | 6/5/20 | 5/24/21 | 5/24/22 | 5/9/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,119 | 2,234 | - | 2,575 | 2,489 | 2,747 | 2,848 | 3,208 | 3,461 | 3,534 | 3,708 |
| EBITDA 1 | 553.3 | 508.7 | - | 557.5 | 464.7 | 646.8 | 710.2 | 871.9 | 972.5 | 921.5 | 988 |
| EBIT | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | 664.3 | 830.4 | - | - | 931 |
| Net income 1 | 375.9 | 382.3 | 345.1 | 361.7 | - | - | 500.1 | 627 | 698 | 666 | 674.5 |
| Net margin | 17.74% | 17.12% | - | 14.04% | - | - | 17.56% | 19.54% | 20.17% | 18.85% | 18.19% |
| EPS 2 | 3.920 | 3.980 | - | 3.770 | - | - | - | 6.530 | 5.600 | 7.200 | 7.200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/29/21 | 11/1/21 | 1/31/22 | 5/24/22 | 8/4/22 | 11/4/22 | 1/28/23 | 8/7/23 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 1,508 | 2,645 | 4,434 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 236 | -306 | -483 | 912 | 2,026 | 2,700 |
| ROE (net income / shareholders' equity) | - | 19.4% | 14.3% | 15.4% | 18.4% | 20.1% | 21.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 108.0 | 113.0 | 129.0 | 150.0 | 178.0 | 213.0 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 2,391 | 1,625 | 1,161 | 1,161 |
| Capex / Sales | - | - | - | 21.44% | 11.92% | 6.97% | 5.74% |
| Announcement Date | 6/5/20 | 5/24/21 | 5/24/22 | 5/9/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1,640
INR
Average target price
1,748
INR
Spread / Average Target
+6.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.97% | 1.89B | |
| -2.54% | 186B | |
| -1.85% | 107B | |
| -4.26% | 67.44B | |
| +1.39% | 50.03B | |
| +16.82% | 47.81B | |
| +4.79% | 41.03B | |
| +3.49% | 26.85B | |
| +0.65% | 25.82B | |
| +16.55% | 24.74B |
- Stock Market
- Equities
- POLYMED Stock
- Financials Poly Medicure Limited
